Kennedy Capital Management, Inc. Phathom Pharmaceuticals, Inc. Transaction History
Kennedy Capital Management, Inc.
- $4.27 Billion
- Q3 2024
A detailed history of Kennedy Capital Management, Inc. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 728,490 shares of PHAT stock, worth $6.36 Million. This represents 0.31% of its overall portfolio holdings.
Number of Shares
728,490
Previous 830,906
12.33%
Holding current value
$6.36 Million
Previous $8.56 Million
53.9%
% of portfolio
0.31%
Previous 0.2%
Shares
6 transactions
Others Institutions Holding PHAT
# of Institutions
144Shares Held
73.6MCall Options Held
42.3KPut Options Held
45.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$88.3 Million9.84% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$65.2 Million28.04% of portfolio
-
Jennison Associates LLC5.87MShares$51.2 Million0.07% of portfolio
-
Invesco Ltd. Atlanta, GA4.1MShares$35.8 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$30.5 Million9.52% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $342M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...